Editas Medicine (EDIT) Net Margin (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Net Margin data on file, last reported at 401.3% in Q3 2025.

• On a quarterly basis, Net Margin rose 10146100.0% year-over-year to 401.3% in Q3 2025; TTM through Sep 2025 was 472.68%, a 12298.0% decrease from a year earlier, with the FY2024 full-year figure at 790.79%, down 17606.0% from the prior year.
• Net Margin for Q3 2025 stood at 401.3%, up from 1452.26% in the prior quarter.
• Over the last five years, Net Margin for EDIT reached as high as 34.01% in Q4 2023 and fell as low as 3785952.38% in Q3 2022.
• Historically, Net Margin has averaged 213070.13% across 5 years, with a median of 2489.11% in 2023.
• Across the five-year window, Net Margin slumped 378486314 bps in 2022 and jumped 378346327 bps in 2023, its largest moves.
• Year by year, Net Margin stood at 270.41% in 2021, then slumped by 227 bps to 885.33% in 2022, then surged by 96 bps to 34.01% in 2023, then plunged by 459 bps to 190.04% in 2024, then plunged by 111 bps to 401.3% in 2025.
• Per Business Quant data, the three most recent Net Margin figures were 401.3% in Q3 2025, 1452.26% in Q2 2025, and 1692.85% in Q1 2025.